nach oben

Urolithiasis

Erschienen in:

01.06.2003 | Invited Editorial

Characteristics of nanobacteria and their possible role in stone formation

verfasst von: E. Olavi Kajander, Neva Ciftcioglu, Katja Aho, Enrique Garcia-Cuerpo

Erschienen in: Urolithiasis | Ausgabe 2/2003

Einloggen, um Zugang zu erhalten

Abstract

Kidney stone formation is a multifactorial disease in which the defence mechanisms and risk factors are imbalanced in favour of stone formation. We have proposed a novel infectious agent, mineral forming nanobacteria (NB), to be active nidi that attach to, invade and damage the urinary epithelium of collecting ducts and papilla forming the calcium phosphate center(s) found in most kidney stones. Stone formation may proceed in urine supersaturated with calcium phosphate, calcium oxalate and uric acid/urate under the influence of crystallization promoters and inhibitors. Our hypothesis underlines the role of active nidi: even supersaturated urine requires nidi for crystallization to appear.

Aho K (2002) In vivo biodistribution and toxicity of nanobacteria in rodents. In: International Nanobacteria Minisymposium, March 8 2001, Kuopio. Book of abstracts, Kuopio University Press, Kuopio, (in press). Abstract at http://www.nanobac.com/nbminisymp080301/page9.html

Aho K, Kajander EO, Ciftcioglu N, Hjelle JT, Miller-Hjelle MA (2002) Screening of human gamma globulin products for nanobacteria markers. American Society for Microbiology, 102nd General Meeting; May 19–23 2002, Salt Lake City. Abstract Y-10, p. 507.

Akerman KK, Kuikka JT, Ciftcioglu N, Parkkinen J, Bergstrom KA, Kuronen I, Kajander EO (1997) Radiolabeling and in vivo distribution of nanobacteria in rabbit. Proc SPIE Int Soc Opt Eng 3111:436

Bjorklund M, Ciftcioglu N, Kajander EO (1998) Extraordinary survival of nanobacteria under extreme conditions. Proc SPIE Int Soc Opt Eng 3441:123

Bone HG3rd, Zerwekh JE, Britton F, Pak CY (1979) Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards. J Urol 121:568PubMed

Burton SK (2001) Nanobacteria growth characteristics and biofilm formation. Proceedings American Society of Microbiology 101st General Meeting, May 20–24, 2001, Orlando. Abstract I-98, p 437

Carr RJ (1954) A new theory of the formation of renal calculi. Brit J Urol 26:105

Ciftcioglu N, Kajander EO (1998) Interaction of nanobacteria with cultured mammalian cells. Pathophysiology 4:259CrossRef

Ciftcioglu N, Kajander EO (2000) Growth factors for nanobacteria. Proc SPIE Int Soc Opt Eng 3755:113

10.

Ciftcioglu N, Pelttari A, Kajander EO (1997) Extraordinary growth phases of nanobacteria isolated from mammalian blood. Proc SPIE Int Soc Opt Eng 3111:429

11.

Ciftcioglu N, Bjorklund M, Kajander EO (1998) Stone formation and calcification by nanobacteria in human body. Proc SPIE Int Soc Opt Eng 3441:105

12.

Ciftcioglu N, Ciftcioglu V, Vali H, Turcott E, Kajander EO (1998) Sedimentary rocks in our mouth: dental pulp stones made by nanobacteria. Proc SPIE Int Soc Opt Eng 3441:130

13.

Ciftcioglu N, Bjorklund M, Kuorikoski K, Bergstrom K, Kajander EO (1999) Nanobacteria: an infectious cause for kidney stone formation. Kidney Int 56:1893CrossRefPubMed

14.

Ciftcioglu N, Miller-Hjelle MA, Hjelle JT, Kajander EO (2002) Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method. Antimicrob Agents Chemother 46:2077CrossRefPubMed

15.

Cisar JO, Xu D-Q, Thompson J, Swaim W, Hu L, Kopecko DJ (2000) An alternative interpretation of nanobacteria-induced biomineralization. Proc Natl Acad Sci U S A 97:11511CrossRefPubMed

16.

Fan J, Chandhoke PS (1999) Examination of crystalluria in freshly voided urines of recurrent calcium stone formers and normal individuals using a new filter technique. J Urol 161:1685PubMed

17.

Folk RL (1993) SEM imaging of bacteria and nannobacteria in carbonate sediments and rocks. J Sediment Petrol 63:990

18.

Garcia Cuerpo E, Kajander EO, Ciftcioglu N, Lovaco Castellano F, Correa C, Gonzalez J, Mampaso F, Liano F, Garcia de Gabiola E, Escudero Barrileiro A (2000): Nanobacteria. Un modelo de neo-litogenesis experimental. Arch Esp Urol 53:291PubMed

19.

Hjelle JT, Miller-Hjelle MA, Poxton IR, Kajander EO, Ciftcioglu N, Jones ML, Caughey RC, Brown R, Millikin PD, Darras FS (2000) Endotoxin and nanobacteria in polycystic kidney disease. Kidney Int 57:2360CrossRefPubMed

20.

Hojgaard I, Fornander AM, Nilsson MA, Tiselius HG (1999) Crystallization during volume reduction of solutions with a composition corresponding to that in the collecting duct: the influence of hydroxyapatite seed crystals and urinary macromolecules. Urol Res 27:417CrossRefPubMed

21.

Holmberg M (2002) Serological evidence for nanobacteria prevalence suggests a possible zoonosis. In: International Nanobacteria Minisymposium, March 8 2001, Kuopio. Book of abstracts, Kuopio University Press, Kuopio, (in press). Abstract at http://www.nanobac.com/nbminisymp080301/page10.html

22.

Kajander EO, Ciftcioglu N (1998) Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci U S A 95:8274CrossRefPubMed

23.

Kajander EO, Ciftcioglu N (2000) Nanobacteria as extremophiles. Proc SPIE Int Soc Opt Eng 3755:106

24.

Kajander EO, Kuronen I, Akerman K, Pelttari A, Ciftcioglu N (1997) Nanobacteria from blood, the smallest culturable autonomously replicating agent on Earth. Proc SPIE Int Soc Opt Eng 3111:420

25.

Kajander EO, Bjorklund M, Ciftcioglu N (1998) Mineralization by nanobacteria. Proc SPIE Int Soc Opt Eng 3441:86

26.

Kajander EO, Heinonen T, Kuronen I, Luoto K, Ciftcioglu N (1999) Nanobacteria, mycoplasma and bacterial L-forms; problems for sterile filtration. In: Wirtanen G, Salo S, Mikkola A (eds) 30th R3-Nordic Contamination Control Symposium, Helsinki, Finland, May 30–June 2, 1999. VTT Technical Research Centre of Finland, Espoo, p 279

27.

Kajander EO, Ciftcioglu N, Aho K (2001) Detection of nanobacteria in viral vaccines. Proceedings of the American Society of Microbiology, 101stGeneral Meeting, 20–24 May 2001, Orlando. Abstract Y-3, p 736.

28.

Kajander EO, Ciftcioglu N, Miller-Hjelle MA, Hjelle JT (2001) Nanobacteria: controversial pathogens in nephrolithiasis and polycystic kidney disease. Curr Opin Neprol Hypertens 10:445CrossRef

29.

Lieske JC, Toback FG (2000) Renal cell-urinary crystal interactions. Curr Opin Neprol Hypertens 9:349CrossRef

30.

Low RK, Stoller ML, Schreiber CK (2000) Metabolic and urinary risk factors associated with Randall's papillary plaques. J Endourol 14:507PubMed

31.

Martini LA, Wood RJ (2000) Should dietary calcium and protein be restricted in patients with nephrolithiasis? Nutr Rev 58:111PubMed

32.

McKay DS, Gibson EKJr, Thomas-Keprta KL, Vali H, Romanek CS, Clemett SJ, Chillier XD, Maechling CR, Zare RN (1996) Search for past life on Mars: Possible relic biogenic activity in Martian meteorite ALH840001. Science 273:924PubMed

33.

Miller-Hjelle MA, Hjelle JT, Ciftcioglu N, Kajander EO (2003). Nanobacteria: methods for growth and identification of this recently discovered calciferous microbe. In: Olson W (ed) Rapid analytical microbiology: the chemistry and physics of microbial identification. Sue Horwood, Storrington (in press)

34.

Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910PubMed

35.

Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817PubMed

36.

Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK (2002) Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix γ-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 277:3926CrossRefPubMed

37.

Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356CrossRefPubMed

38.

Puskás L (2002) Detection of nanobacteria in human atherosclerotic plaques. In: International Nanobacteria Minisymposium, March 8 2001, Kuopio. Book of abstracts, Kuopio University Press, Kuopio, (in press). Abstract at http://www.nanobac.com/nbminisymp080301/page13.html

39.

Ramello A, Vitale C, Marangella M (2000) Epidemiology of nephrolithiasis. J Nephrol 13:S45PubMed

40.

Randall A (1937) The origin and growth of renal calculi. Ann Surg 105:1009

41.

Scheinmann SJ (1999) Nephrolithiasis. Semin Nephrol 19:381PubMed

42.

Schwartz BF, Bruce J, Leslie S, Stoller ML (2001) Rethinking the role of urinary magnesium in calcium urolithiasis. J Endourol 15:233CrossRefPubMed

43.

Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB (1999) Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10 (Suppl 14):S334PubMed

44.

Sommer AP, Pinheiro AL, Mester AR, Franke RP, Whelan HT (2001) Biostimulatory windows in low-intensity laser activation: lasers, scanners and NASA's light-emitting diode array system. J Clin Laser Med Surg 19:29CrossRefPubMed

45.

Sommer AP, Hassinen HI, Kajander EO (2002) Light induced replication of nanobacteria-a preliminary report. J Clin Laser Med Surg 20:241CrossRefPubMed

46.

Sommer AP, Oron U, Kajander EO, Mester AR (2002) Stressed cells survive better with light. J Proteome Res 1:475CrossRef

47.

Söhnel O, Grases F (1993) Fine structure of calcium oxalate monohydrate renal calculi. Nephron 63:176PubMed

48.

Uwins PJR, Webb RI, Taylor AP (1998) Novel nano-organisms from Australian sandstones. Am Minerol 83:1541

49.

Vali H, McKee MD, Ciftcioglu N, Sears SK, Plows FL, Chevet E, Ghiasi P, Plavsic M, Kajander EO, Zare RN (2001) Nanoforms: a new type of protein-associated mineralization. Geochim Cosmochim Acta 65:63CrossRef

50.

Wahl C, Hess B (2000) Kidney calculi – is nutrition a trigger or treatment? Ther Umsch 57:138PubMed

51.

Wainwright M (1999) Nanobacteria and associated 'elementary bodies' in human disease and cancer. Microbiology 145:2623PubMed

52.

Ylitalo R (2002) Bisphosphonates and atherosclerosis. Gen Pharmacol 35:287

Titel: Characteristics of nanobacteria and their possible role in stone formation
verfasst von: E. Olavi Kajander
Neva Ciftcioglu
Katja Aho
Enrique Garcia-Cuerpo
Publikationsdatum: 01.06.2003
Verlag: Springer-Verlag
Erschienen in: Urolithiasis / Ausgabe 2/2003
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-003-0304-7

Neu im Fachgebiet Urologie

Schützt auch die medikamentöse Gewichtsreduktion vor Krebs?

03.06.2024 ASCO 2024 Kongressbericht

Offenbar muss es nicht immer die bariatrische Chirurgie sein, wenn es darum geht, durch deutlichen Gewichtsverlust auch das Krebsrisiko günstig zu beeinflussen. Eine große Kohortenanalyse zur Behandlung mit GLP-1-Agonisten wurde dazu auf der ASCO-Tagung vorgestellt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Characteristics of nanobacteria and their possible role in stone formation

Abstract

Neu im Fachgebiet Urologie

Schützt auch die medikamentöse Gewichtsreduktion vor Krebs?

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Update Urologie

Adipositas in der Primärversorgung – Herausforderungen und Chancen einer ganzheitlichen Betreuung

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2003

Differences in the quantity of elastic fibres and collagen type I and type III in endopelvic fascia between women with stress urinary incontinence and controls

Is serotonin significant for the control of penile flaccidity and detumescence in the human male?

Abstracts of the 10th EULIS Symposium

Systemic and cavernous plasma levels of vasopressin in healthy males during different functional conditions of the penis

Neu im Fachgebiet Urologie

Schützt auch die medikamentöse Gewichtsreduktion vor Krebs?

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Update Urologie